帕尼培南-倍他米隆体外抗菌活性及其对肺部感染病人的疗效观察

目的 :了解帕尼培南 倍他米隆对临床常见致病菌的体外抗菌活性及治疗肺部感染的有效性及安全性。方法 :采用琼脂二倍稀释法测定帕尼培南 倍他米隆对 2 4 7株临床分离菌的MIC ,检测其对部分菌株的最低杀菌浓度 ;2 0例肺部感染病人使用帕尼培南 倍他米隆 5 0 0 /5 0 0mg ,q 12h ,iv ,gtt ,疗程3～ 7d。结果 :帕尼培南 倍他米隆与帕尼培南的体外抗菌活性基本一致 ,MIC50 ≤ 0 .0 0 75mg·L- 1,MIC90 为 0 .0 0 75～ 2mg·L- 1;对流感嗜血杆菌的MIC范围为 <0 .0 0 75～ 0 .12 5mg·L- 1;对阴沟肠杆菌、变形肠杆菌、铜绿假单孢菌的MIC50 和MIC90 分别为 0 .12 5和 0 .5 ,2和 4 ,4和 16mg·L- 1;帕尼培南 倍他米隆对金黄色葡萄球菌、表皮葡萄球菌、铜绿假单孢菌、肺炎克雷伯菌、大肠埃希菌、阴沟肠杆菌、变形肠杆菌及微球菌的最低杀菌浓度分别是其MIC的 1～ 8倍。致病菌阴转率为 77.8% ,治疗有效率为 75 % ,未出现明显不良反应。结论 :帕尼培南 倍他米隆对临床常见致病菌的体外抗菌活性强 ;对肺部感染有较好疗效 ,安全性好

Antibacterial activity of panipenem/betamipron in vitro and its therapeutic efficacy in patients with pulmonary infection

AIM: To investigate the in vitro antibacterial activity of panipenem/betamipron to clinical farmiliar pathogen and to estimate its clinical effect and safety in treating pulmonary infection. METHODS: The minimal inhibition concentrations(MICs) of panipenem/betamipron to 247 clinical isolates were determined by agar dilution method. The minimal bactericidal concentrations (MBCs) of panipenem/betamipron to some clinical isolates were determined. Twenty patients with pulmonary infection were treated with panipenem/betamipron 500/500 mg, q 12 h, iv, gtt, for 3-7 d, at the some time bacterial culture results and the efficacy were observed. RESULTS: The in vitro antibacterial activity of panipenem/betamipron was almost the same as that of panipenem. Panipenem/betamipron had a strong antibacterial activity against Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, β-Streptococcus hemolytic, Streptococcus pneumonia, Micrococcus, Escherichia coli and Klebsiella pneumonia.MIC 50 and MIC 90 to these bacteria strains were about ≤ 0.0075 mg·L -1 and <0.0075-2 mg·L -1, respectively. The drug had also showed a potent effect against Haemophilus influenzae (MIC rang<0.0075-0.125 mg·L -1). MIC 50/MIC 90 to Enterobacter cloacae, Proteus, and Pseudomonas aeruginosa were 0.125/0.5,2/4,4/16 mg·L -1, respectively. The MBC of panipenem/betamipron to Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia coli, Enterobacter cloacae, Protes, and Micrococcus were 1-8 times than that of MIC, respectively. The eradication rate of bacteria was 77.8% and the effective rate of panipenem was 75%, respectively. No adverse reaction appeared. CONCLUSION: Panipenem/betamipron has a strong in vitro antibacterial activity against clinical of ten-seen pathogen and is effective and safe for treatment of pulmonary infection.